Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

ACCORD HEALTHCARE, INC.

US Class II Terminated · initiated 2024-10-01

Failed Impurities/Degradation Specifications.

Glenmark Pharmaceuticals Inc., USA

US Class III Ongoing · initiated 2024-09-30

Defective Container: Firm received complaints of broken tube at the seal.

Staska Pharmaceuticals, Inc.

US Class I Terminated · initiated 2024-09-30

Presence of Particulate Matter: Presence of glass particulates.

M-Eslon capsule

Canada Type I Ongoing · initiated 2024-09-27

Labelling. Check your M-Eslon (morphine sulfate) medication bottle or package. If your prescription is for 30 mg, the capsules should be pink and clear. If it c…

Mint-Risperidon 0.25 mg tablet

Canada Type II Ongoing · initiated 2024-09-27

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

CGMP violations

Fresenius Kabi Compounding, LLC

US Class II Terminated · initiated 2024-09-25

cGMP violations

Denison Pharmaceuticals, LLC

US Class III Ongoing · initiated 2024-09-25

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Denison Pharmaceuticals, LLC

US Class III Ongoing · initiated 2024-09-25

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Cromolyn eye drops

Canada Type II Ongoing · initiated 2024-09-25

Product quality. Do not use the affected product. Return it to your local pharmacy for proper disposal.Consult a health care professional if you have used this …

Nivagen Pharmaceuticals Inc

US Class II Terminated · initiated 2024-09-24

Presence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg…

Glenmark Pharmaceuticals Inc., USA

US Class II Ongoing · initiated 2024-09-24

Defective Delivery System: The dip tube is clogged causing the spray not to work.

VIONA PHARMACEUTICALS INC

US Class II Ongoing · initiated 2024-09-24

Crystallization

Advanced Accelerator Applications USA, Inc.

US Class II Ongoing · initiated 2024-09-23

CGMP deviations

Gilead Sciences, Inc.

US Class I Terminated · initiated 2024-09-19

Presence of Particulate Matter: Presence of glass particle.

EnviroServe Chemicals Inc.

US Class II Ongoing · initiated 2024-09-18

CGMP deviations

123Herbals

US Class I Ongoing · initiated 2024-09-18

Marketed without an approved NDA/ANDA: Product found to be tainted with undeclared dexamethasone and chlorpheniramine.